Crinetics Pharmaceuticals Inc
Research Crinetics Pharmaceuticals Inc (CRNX) on Bullrun: market cap USD 8.98B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRNX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.98B
- Financial periodQ2 2026
- RevenueUSD 25.12M
- Net income-USD 120.86M
- Free cash flow-USD 94.71M
- Gross margin99.4%
Valuation Snapshot
latest market cap is USD 8.98B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 7.70M | -USD 465.30M | -USD 383.68M | 86.0% | -4.95 | USD 101.54M | USD 48.54M | USD 992.08M |
| FY2024 | USD 1.04M | -USD 298.40M | -USD 234.04M | 100.0% | -3.69 | USD 264.55M | USD 51.72M | USD 1.32B |
| FY2023 | USD 4.01M | -USD 214.50M | -USD 173.29M | 100.0% | -3.69 | USD 54.90M | USD 51.73M | USD 539.11M |
| FY2022 | USD 0 | -USD 163.90M | -USD 116.86M | n/a | -3.15 | USD 32.67M | USD 2.57M | USD 316.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.98B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.45B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.75B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.38B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 984.73M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.35B | n/a | n/a | n/a |
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Crinetics Pharmaceuticals Inc's market cap?
Crinetics Pharmaceuticals Inc's market capitalization is USD 8.98B.
What does Crinetics Pharmaceuticals Inc do?
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.